As BIO2025 approaches, we’re excited to share that Caszyme CEO, Monika Paule, is featured in The Pharma Navigator.
In this recent video interview, Monika highlights the capabilities of our novel Cas12l nuclease family, emphasizing its unique features and key advantages over Cas9, especially in overcoming size and IP limitations in CRISPR gene editing.
Monika also shares her excitement about the BIO International Convention in Boston, where the industry buzzes with innovation, looking forward to reconnecting with partners and meeting new companies.
We’d love to connect – visit us at the Lithuanian Booth No.1057, or reach out to schedule a meeting in advance.
Before BIO kicks off, take a moment to watch the full interview.